Evidence map›Paper›PMID 36812589›Full record

ArticlePLOS digital health2022

Large-scale application of named entity recognition to biomedicine and epidemiology.

Shaina Raza, Deepak John Reji, Femi Shajan, Syed Raza Bashir

Open access · goldAbstract read
In one paragraph

Article in PLOS digital health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Utilizing Large Language Models for Zero-Shot Medical Ontology Extension from Clinical Notes.Proceedings. IEEE International Conference on Bioinformatics and Biomedicine · 2025
    Article
  5. Article
  6. Article
  7. Do LLMs Surpass Encoders for Biomedical NER?Proceedings. IEEE International Conference on Healthcare Informatics · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Automating Clinical Trial Matches Via Natural Language Processing of Synthetic Electronic Health Records and Clinical Trial Eligibility Criteria.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2024
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Shaina RazaDalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-1061-5845
Deepak John RejiEnvironmental Resources Management, Bangalore, India.
Femi ShajanEnvironmental Resources Management, Bangalore, India.
Syed Raza BashirToronto Metropolitan University, Toronto, Ontario, Canada.
Toronto Metropolitan University · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite significant advancements in biomedical named entity recognition methods, the clinical application of these systems continues to face many challenges: (1) most of the methods are trained on a limited set of clinical entities; (2) these methods are heavily reliant on a large amount of data for both pre-training and prediction, making their use in production impractical; (3) they do not consider non-clinical entities, which are also related to patient's health, such as social, economic or demographic factors.

methodsIn this paper, we develop Bio-Epidemiology-NER (https://pypi.org/project/Bio-Epidemiology-NER/) an open-source Python package for detecting biomedical named entities from the text. This approach is based on a Transformer-based system and trained on a dataset that is annotated with many named entities (medical, clinical, biomedical, and epidemiological). This approach improves on previous efforts in three ways: (1) it recognizes many clinical entity types, such as medical risk factors, vital signs, drugs, and biological functions; (2) it is easily configurable, reusable, and can scale up for training and inference; (3) it also considers non-clinical factors (age and gender, race and social history and so) that influence health outcomes. At a high level, it consists of the phases: pre-processing, data parsing, named entity recognition, and named entity enhancement.

resultsExperimental results show that our pipeline outperforms other methods on three benchmark datasets with macro-and micro average F1 scores around 90 percent and above.

conclusionThis package is made publicly available for researchers, doctors, clinicians, and anyone to extract biomedical named entities from unstructured biomedical texts.

Identifiers

PMID36812589
PMCPMC9931203
OpenAlexW4311829616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.